LifeMap Sciences Announces Release and Commercial Availability of GeneAnalytics 1.0, a Powerful Gene Set Analysis …
Posted: October 6, 2014 at 8:41 am
ALAMEDA, Calif.--(BUSINESS WIRE)--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the commercial release of GeneAnalytics 1.0 at http://www.geneanalytics.com. GeneAnalytics is a powerful, yet easy to use, gene set analysis tool designed to help life scientists and biomedical researchers identify expression signatures and functionality of their experimental gene sets, and define their roles in various biological processes and in health and disease.
GeneAnalytics is powered by LifeMap Sciences popular integrated knowledgebase and discovery platform for biomedical research, which includes: GeneCards (http://www.genecards.org), the human gene database, LifeMap Discovery (http://discovery.lifemapsc.com), the embryonic development and stem cell database and MalaCards (http://www.malacards.org), the human disease database. LifeMap Sciences holds the exclusive worldwide license to market GeneCards and MalaCardsfrom Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science.
LifeMap Sciences Biomedical Knowledgebase enables GeneAnalytics to analyze experimental gene sets of interest and match them toexpression patterns in various cell types, diseases and pathways and functional groups. It can aid in the discovery ofmarkers for tissues, cells and diseases, investigation ofdiseasemechanisms and in exploration of relationships between compounds and gene networks to enhance drug discovery. It is also a unique tool for characterization of tissue samples and cultured cells, assessment of their purity and analysis ofoutcomes of cell differentiation experiments.
GeneAnalytics is a key component of LifeMap Sciences recently launched premium platform, GeneCards Plus. The platform also includes GeneALaCart (http://genealacart.genecards.org), the GeneCards batch querying application and VarElect (http://varelect.genecards.org), the Next Generation Sequencing phenotyper.
Ronit Shtrichman, Ph.D., Vice President of Biology at LifeMap Sciences said, We believe that leveraging our extensive information and knowledgebase on biological entities, such as genes, cells, pathways, compounds and diseases, and the connections between these various entities to power gene set analysis by GeneAnalytics will enable it to significantly enhance basic biomedical research, stem cell research and therapeutic discovery.
In the few months since weve launched the beta version of GeneAnalytics, weve had over 1,000 scientists from academia and industry use it in their research, said Yaron Guan-Golan, Head of Marketing at LifeMap Sciences. This is evidence that GeneAnalytics is a powerful research aid and we look forward to continuously improve its capabilities and features in upcoming releases, together with GeneALaCart and VarElect, our premium GeneCards Plus research tools.
About LifeMap Sciences, Inc.
LifeMap Sciences (www.lifemapsc.com) core technology and business is based on its Integrated Biomedical Knowledgebase and discovery platform for biomedical research, which currently includesGeneCards: the leading human gene database;LifeMap Discovery, the database of embryonic development, stem cell research and regenerative medicine;MalaCards, the human disease database; and GeneAnalytics, a novel gene set analysis tool which leverages our Integrated Biomedical Knowledgebase. LifeMaps products are used in more than 3,000 institutions including academia, research hospitals, patent offices, and leading biotechnology and pharmaceutical companies.
LifeMap Sciences intends to continually improve the quality of its products, and is pursuing several new Internet and informatics products with substantial, rapid-revenue growth potential, leveraging its existing products and their large user base of life scientists. LifeMap also intends to extend its offerings to the field of mobile health via its subsidiaryLifeMap Solutions, Inc.
About BioTime